title: Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study.
authors.affiliation: Department of Medicine, Helsinki University Central Hospital, PB 340, FIN 00029 HUS Helsinki, Finland. karin.mattson@hus.fi
authors.forename: K
authors.initials: K
authors.lastname: Mattson
authors.forename: R
authors.initials: R
authors.lastname: Abratt
authors.forename: G V
authors.initials: GV
authors.lastname: Ten
authors.forename: K
authors.initials: K
authors.lastname: Krofta
authors.forename: D
authors.initials: D
authors.lastname: Tonelli
authors.forename: I
authors.initials: I
authors.lastname: Avril
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016019:Survival Analysis; D043823:Taxoids
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel